feb jan dec nov oct sep fda drugs march zenvia for involuntary emotional expression disorder avanir pharm received an approvable letter last october for its zenvia , which is a combination drug of dextromethorphan quinidine dm q used to treat what is otherwise known as labile affect or pseudobulbar affect , a brain condition where one will have uncontrollable bursts of laughing or crying without truly being happy or sad this typically occurs after a stroke or with pseudobulbar palsy or als the fda had required more data , which the company recently provided at a meeting the dm is an nmda antagonist , and quinidine is being used here as a p cypd enzyme inhibitor , which makes the drug stick around longer the fda asked avanir to resubmit a new nda for a lower , safer dose pubmed cephalon gets yet another warning letter on provigil the fda dinged cephalon again in this feb letter about inappropriate marketing claims suggesting that provigil is effective for certain conditions when these data have not been submitted or approved by the fda marijuana based drug gathering data sativex is an oral spray containing two active compounds from the cannabis sativa plant being developed for several conditions , including ms related spasticity , aids related anorexia , and neuropathic pain given the fact that it is directly derived from pot plants and the u s paranoia about marijuana , i'm sure this drug has a long , uphill battle to get approved here pubmed prozac labeling change for infants the labeling information for prozac fluoxetine now has added info on the risk of primary pulmonary hypotension pph in drug exposed newborns precautions pregnancy nonteratogenic effects infants exposed to ssris in late pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn pphn pphn occurs in per live births in the general population and is associated with substantial neonatal morbidity and mortality in a retrospective case control study of women whose infants were born with pphn and women whose infants were born healthy , the risk for developing pphn was approximately six fold higher for infants exposed to ssris after the th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy there is currently no corroborative evidence regarding the risk for pphn following exposure to ssris in pregnancy this is the first study that has investigated the potential risk the study did not include enough cases with exposure to individual ssris to determine if all ssris posed similar levels of pphn risk i do n't know if all ssris will get this language the link goes to the original nejm article new fda info sheets on invega paliperidone keppra levetiracetam trileptal oxcarbazepine permax recalled the fda announced that the dopamine agonist , permax pergolide , has been voluntarily recalled due to concerns about damage to heart valves permax was used to treat parkinson 's disease and restless legs syndrome phase iii trials started on flurizan for alzheimer 's this looks like a promising drug from myriad to keep track of geodon label updated the labeling info for geodon ziprasidone was updated in the patient summary section , to include the black box warning about diabetes and also include the more recent indications for manic and mixed episodes of bipolar disorder symmetrel label updated apparently , there have been some reports of agranulocytosis dangerous drop in white blood cell wbc count with symmetrel amantadine , which is used as an antiviral , for parkinsons , for pain , and probably a few other things the labeling info now reflects this fda adds warnings on all sleeping pills the fda has asked that all makers of sedative hypnotics , like ambien , sonata , and lunesta , add warnings to their labels about anaphylaxis severe allergic reaction and angioedema severe facial swelling , which can occur as early as the first time the product is taken and complex sleep related behaviors which may include sleep driving , making phone calls , and preparing and eating food while asleep the warning affects the following drugs and their manufacturers ambien ambien cr sanofi aventis butisol sodium medpointe pharm hlc carbrital parke davis dalmane valeant pharm doral questcor pharms halcion pharmacia upjohn lunesta sepracor placidyl abbott prosom abbott restoril tyco healthcare rozerem takeda seconal lilly sonata king pharmaceuticals